Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77,331,078
-
Total 13F shares
-
27,692,215
-
Share change
-
+9,007,117
-
Total reported value
-
$313,869,842
-
Price per share
-
$11.34
-
Number of holders
-
69
-
Value change
-
+$101,491,026
-
Number of buys
-
39
-
Number of sells
-
30
Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q1 2020
As of 31 Mar 2020,
Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by
69 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,692,215 shares.
The largest 10 holders included
Avoro Capital Advisors LLC, BVF INC/IL, ADAGE CAPITAL PARTNERS GP, L.L.C., Consonance Capital Management LP, ORBIMED ADVISORS LLC, FMR LLC, Aquilo Capital Management, LLC, EVENTIDE ASSET MANAGEMENT, LLC, Capital International Investors, and NEA Management Company, LLC.
This page lists
69
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.